Chronic myeloid leukaemia (CML) is a type of blood cancer where too many myeloid cells are produced – immature white blood cells that are not fully developed and do not work properly.
CML tends to progress slowly over many years.
CML can occur at any age, but is most common in older adults around 60-65 years of age.
The main treatment for CML are tyrosine kinase inhibitors, such as imatinib.
CML is classically associated with the Philadelphia chromosome.
Cancer Research UK - CML
©2021 Royal College of Physicians of Edinburgh
A charity registered in Scotland no. SC009465